ARTL Quote, Financials, Valuation and Earnings

Spectral AI has a net margin of -- compared to Artelo Biosciences's net margin of 43.19%. Artelo Biosciences's return on equity of -- beat Spectral AI's return on equity of -4727.7%.

Artelo Biosciences has a consensus price target of $20.00, signalling upside risk potential of 31.75%. On the other hand Spectral AI has an analysts' consensus of $5.09 which suggests that it could grow by 87.82%. Given that Spectral AI has higher upside potential than Artelo Biosciences, analysts believe Spectral AI is more attractive than Artelo Biosciences.

Artelo Biosciences has a beta of 1.338, which suggesting that the stock is 33.77% more volatile than S&P 500. In comparison Spectral AI has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Artelo Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spectral AI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artelo Biosciences pays -- of its earnings as a dividend. Spectral AI pays out -- of its earnings as a dividend.

Artelo Biosciences quarterly revenues are --, which are smaller than Spectral AI quarterly revenues of $6.7M. Artelo Biosciences's net income of -$2.4M is lower than Spectral AI's net income of $2.9M. Notably, Artelo Biosciences's price-to-earnings ratio is -- while Spectral AI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artelo Biosciences is -- versus 1.79x for Spectral AI. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Artelo Biosciences's net margin of -907.48%. Artelo Biosciences's return on equity of -- beat Moderna's return on equity of -29.23%.

Artelo Biosciences has a consensus price target of $20.00, signalling upside risk potential of 31.75%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Artelo Biosciences, analysts believe Moderna is more attractive than Artelo Biosciences.

Artelo Biosciences has a beta of 1.338, which suggesting that the stock is 33.77% more volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Artelo Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artelo Biosciences pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Artelo Biosciences quarterly revenues are --, which are smaller than Moderna quarterly revenues of $107M. Artelo Biosciences's net income of -$2.4M is higher than Moderna's net income of -$971M. Notably, Artelo Biosciences's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artelo Biosciences is -- versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Artelo Biosciences's net margin of -49.65%. Artelo Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Artelo Biosciences has a consensus price target of $20.00, signalling upside risk potential of 31.75%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Artelo Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Artelo Biosciences is more attractive than NovaBay Pharmaceuticals.

Artelo Biosciences has a beta of 1.338, which suggesting that the stock is 33.77% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Artelo Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artelo Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Artelo Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Artelo Biosciences's net income of -$2.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Artelo Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artelo Biosciences is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vor Biopharma has a net margin of -- compared to Artelo Biosciences's net margin of --. Artelo Biosciences's return on equity of -- beat Vor Biopharma's return on equity of --.

Artelo Biosciences has a consensus price target of $20.00, signalling upside risk potential of 31.75%. On the other hand Vor Biopharma has an analysts' consensus of $1.18 which suggests that it could fall by -44.58%. Given that Artelo Biosciences has higher upside potential than Vor Biopharma, analysts believe Artelo Biosciences is more attractive than Vor Biopharma.

Artelo Biosciences has a beta of 1.338, which suggesting that the stock is 33.77% more volatile than S&P 500. In comparison Vor Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Artelo Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artelo Biosciences pays -- of its earnings as a dividend. Vor Biopharma pays out -- of its earnings as a dividend.

Artelo Biosciences quarterly revenues are --, which are smaller than Vor Biopharma quarterly revenues of --. Artelo Biosciences's net income of -$2.4M is higher than Vor Biopharma's net income of -$32.5M. Notably, Artelo Biosciences's price-to-earnings ratio is -- while Vor Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artelo Biosciences is -- versus -- for Vor Biopharma. Usually stocks with elevated PS ratios are considered overvalued.